Bernzott Capital Advisors Acquires 94,529 Shares of Enovis Corporation $ENOV

Bernzott Capital Advisors raised its holdings in Enovis Corporation (NYSE:ENOV) by 47.4% during the 1st quarter, HoldingsChannel.com reports. The fund owned 294,125 shares of the company’s stock after acquiring an additional 94,529 shares during the quarter. Enovis accounts for approximately 3.2% of Bernzott Capital Advisors’ investment portfolio, making the stock its 13th largest holding. Bernzott Capital Advisors’ holdings in Enovis were worth $6,691,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of ENOV. AQR Capital Management LLC increased its position in shares of Enovis by 12.5% in the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after purchasing an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after purchasing an additional 73,116 shares during the last quarter. Empowered Funds LLC lifted its position in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after purchasing an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. Finally, Amundi grew its stake in Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after buying an additional 9,762 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Insider Activity

In other news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the acquisition, the insider directly owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This represents a 2.37% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased a total of 4,200 shares of company stock valued at $92,084 in the last quarter. 2.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Evercore set a $32.00 price objective on shares of Enovis in a research report on Monday. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Monday. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Enovis in a research note on Friday, May 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. Finally, Wells Fargo & Company dropped their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Eight analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Enovis has a consensus rating of “Moderate Buy” and an average target price of $41.71.

Enovis Price Performance

Shares of Enovis stock opened at $25.17 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. Enovis Corporation has a 52-week low of $19.14 and a 52-week high of $36.82. The company has a fifty day moving average of $23.34 and a 200-day moving average of $23.79. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -1.27 and a beta of 1.39.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million for the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts expect that Enovis Corporation will post 3.12 EPS for the current year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.